IN8bio, Inc.
INAB
$1.87
-$0.04-2.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -23.64% | -24.37% | -21.63% | -15.96% | -6.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.90% | -32.75% | -28.69% | -15.40% | -3.48% |
| Operating Income | 32.90% | 32.75% | 28.69% | 15.40% | 3.48% |
| Income Before Tax | 36.13% | 35.19% | 25.25% | 11.66% | -1.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.13% | 35.19% | 25.25% | 11.66% | -1.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.13% | 35.19% | 25.25% | 11.66% | -1.43% |
| EBIT | 32.90% | 32.75% | 28.69% | 15.40% | 3.48% |
| EBITDA | 34.84% | 35.05% | 31.04% | 16.50% | 3.71% |
| EPS Basic | 73.91% | 71.33% | 59.35% | 47.68% | 40.28% |
| Normalized Basic EPS | 72.91% | 70.44% | 62.08% | 50.15% | 43.23% |
| EPS Diluted | 73.91% | 71.33% | 59.35% | 47.68% | 40.28% |
| Normalized Diluted EPS | 72.91% | 70.44% | 62.08% | 50.15% | 43.23% |
| Average Basic Shares Outstanding | 158.16% | 144.42% | 112.31% | 85.34% | 80.47% |
| Average Diluted Shares Outstanding | 158.16% | 144.42% | 112.31% | 85.34% | 80.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |